M&A Deal Summary

TerSera Therapeutics Acquires Lexicon Pharmaceuticals - XERMELO

On July 30, 2020, TerSera Therapeutics acquired life science company Lexicon Pharmaceuticals - XERMELO from Lexicon Pharmaceuticals for 159M USD

Acquisition Highlights
  • This is TerSera Therapeutics’ 1st transaction in the Life Science sector.
  • This is TerSera Therapeutics’ largest (disclosed) transaction.
  • This is TerSera Therapeutics’ 1st transaction in the United States.
  • This is TerSera Therapeutics’ 1st transaction in Texas.

M&A Deal Summary

Date 2020-07-30
Target Lexicon Pharmaceuticals - XERMELO
Sector Life Science
Buyer(s) TerSera Therapeutics
Sellers(s) Lexicon Pharmaceuticals
Deal Type Divestiture
Deal Value 159M USD

Target

Lexicon Pharmaceuticals - XERMELO

The Woodlands, Texas, United States
Lexicon Pharmaceuticals's XERMELO is an approved oral therapy for carcinoid syndrome diarrhea. It targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells. XERMELO is approved in the United States, the European Union, and certain additional countries for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Carcinoid syndrome is a rare condition that occurs in patients living with mNETs and is characterized by frequent and debilitating diarrhea. XERMELO targets the overproduction of serotonin inside mNET cells, providing an additional treatment option for patients suffering from carcinoid syndrome diarrhea.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

TerSera Therapeutics

Lake Forest, Illinois, United States

Category Company
Founded 2016
Sector Life Science
DESCRIPTION

TerSera Therapeutics is a specialty pharmaceutical company focused on therapeutics to improve patient outcomes. The company was formed to acquire specialty pharmaceutical companies and products with a focus on select physician specialties. TerSera Therapeutics was founded in 2016 and is based in Lake Forest, Illinois.


DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
State (Texas) 1 of 1
Country (United States) 1 of 2
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-10-22 MARGENZA

Rockville, Maryland, United States

MARGENZA is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors.

Buy -

Seller(S) 1

SELLER

Lexicon Pharmaceuticals

The Woodlands, Texas, United States

Category Company
Founded 1995
Sector Life Science
Employees285
Revenue 1M USD (2023)
DESCRIPTION

Lexicon Pharmaceuticals is a bio-pharmaceutical company focused on the development of breakthrough treatments for human disease. Lexicon Pharmaceuticals was founded in 1995 and is based in The Woodlands, Texas.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Texas) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-08-02 Symphony Icon

United States

Symphony Icon Inc. is a drug development company.

Buy $90M